结核病治疗缩短方案:最新情况和未来的优先事项
Francesca Saluzzo1,2, Victor Abiola Adepoju3,2, Raquel Duarte4,5,6,7
1Vita-Salute San Raffaele University, Milan, Italy.
Breathe (Sheffield, England)
|October 13, 2023
概括
新的药物治疗方案显著缩短了结核病 (TB) 治疗时间. 四项试验表明对药物敏感性和多药耐药性结核病的疗效,但需要进一步研究才能获得最佳使用.
科学领域:
- 传染性疾病 传染性疾病
- 微生物学 微生物学
- 临床药理学 临床药理学
背景情况:
- 结核病 (TB) 治疗持续时间在过去两年中取得了显著的进步.
- 在临床试验中,新药和重新定位的药物已在缩短结核病治疗方案方面显示出有效性.
研究的目的:
- 审查新的结核病治疗方案的证据.
- 确定结核病治疗缩短的剩余问题和正在进行的研究.
主要方法:
- 分析了四项主要临床试验的数据:研究31/A5349,Nix-TB,ZeNix和TB-PRACTECAL.
- 对药物敏感性和耐药性结核病的新药疗法进行评估.
主要成果:
- 4个月的治疗方案对对药物敏感的结核病有效.
- 六个月的贝达基林-普雷托曼尼德-林佐利德疗法 (含或不含莫西弗洛克萨) 对多药耐药/耐利素结核病有效.
结论:
- 尽管有令人信服的证据,但仍然存在关于linezolid剂量,贝达基林耐药性和儿科适用性的开放问题.
- 目前正在进行的试验旨在解决这些差距,并提供进一步的证据来证明结核病治疗的缩短.
相关概念视频
Pulmonary Tuberculosis V
184
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
184
Pulmonary Tuberculosis IV
146
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
146
Pulmonary Tuberculosis I
247
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
247
Pulmonary Tuberculosis II
244
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
244
Pulmonary Tuberculosis III
343
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
The first classification is based on the development of the disease, and it includes the following categories:
343
Pneumonia IV: Management
350
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
350


